Immunochemical detection of human uterine endometrial cancer cell
AssigneesMochida Pharmaceutical Co., Ltd., Shiro Nozawa
InventorsShiro Nozawa, Katsumi Tsukazaki, Motoko Kawamoto
Life of this patent
Estimating the term…
Abstract
A method of screening for the endometrial cancer cells in a endometrial cell specimen is disclosed. The method involves determining the amount of an endometrial cancer associated antigen relative to the sample amount by immunologically detecting and comparing the levels of the endometrial cancer associated antigen and a substance present in human cells in a substantially constant amount.
Claims12
A method of screening for the presence of endometrial cancer cells in an endometrial cell specimen, comprising the steps of
- (a) preparing an endometrial cell specimen by collecting endometrial cells from the cavity of the uterus,
- (b) immobilizing a predetermined amount of said specimen on two or more reaction areas on one or more carriers,
- (c) contacting one of said reaction areas with a monoclonal antibody labelled with a labelling agent, wherein said monoclonal antibody specifically binds an endometrial cancer associated antigen,
- (d) contacting another of said reaction areas with an antibody B labelled with a labelling agent, wherein said antibody B specifically binds a substance A which is present in human cells in a substantially constant amount,
- (e) washing said reaction areas to remove unbound labelled monoclonal antibody and unbound labelled antibody B, and
- (f) measuring a signal intensity y of bound said labelled monoclonal antibody as a measure of the level of endometrial cancer associated antigen and measuring a signal intensity x of bound said labelled antibody B as a measure of the level of substance A,
- (g) wherein an elevated level of the endometrial cancer associated antigen relative to the level of substance A is associated with the presence of endometrial cancer cells in the endometrial cell specimen.
A method of screening for the presence of endometrial cancer cells in an endometrial cell specimen, comprising the steps of
- (a) preparing an endometrial cell specimen by collecting endometrial cells from the cavity of the uterus,
- (b) immobilizing a predetermined amount of said specimen on two or more reaction areas on one or more carriers,
- (c) contacting one of said reaction areas with a monoclonal antibody which specifically binds an endometrial cancer associated antigen,
- (d) contacting another of said reaction areas with an antibody B which specifically binds a substance A which is present in human cells in a substantially constant amount,
- (e) contacting the reaction area of step (c) with an antibody C labelled with a labelling agent, wherein said antibody C specifically binds said monoclonal antibody,
- (f) contacting the reaction area of step (d) with an antibody D labelled with a labelling agent, wherein said antibody D specifically binds said antibody B,
- (g) washing said reaction areas to remove unbound monoclonal antibody, unbound antibody B, unbound labelled antibody C and unbound labelled antibody D, and
- (h) measuring signal intensity y of bound said labelled antibody C as a measure of the level of endometrial cancer associated antigen and measuring a signal intensity of bound said labelled antibody D as a measure of the level of substance A,
- (i) wherein an elevated level of the endometrial cancer associated antigen relative to the level of substance A is associated with the presence of endometrial cancer cells in the endometrial cell specimen.
Dependencies are inferred from the claim text.